Review



cd45 apc antibody  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Miltenyi Biotec cd45 apc antibody
    Cd45 Apc Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 308 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/CD45+Antibody%2C+anti-human%2C+REAfinity/pmc13371841-54-17-19
    Average 96 stars, based on 308 article reviews
    cd45 apc antibody - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    Control:

    Article Title: Cell population comprising mesenchymal cells, pharmaceutical composition comprising the same, and method for producing the same
    Article Snippet: .. In the measurement, REA Control Antibody (S) APC (Miltenyi Biotec, Clone: REA293; Model: 130-113-434) was used as the isotype control antibody, the APC anti-human CD324 antibody (Miltenyi Biotec, Clone: REA811; Model: 130-111-840) was used as the antibody targeting the CD324 antigen, the APC anti-human CD73 antibody (Miltenyi Biotec, Clone: REA804; Model: 130-111-909) was used as the antibody targeting the CD73 antigen, the APC anti-human CD90 antibody (Miltenyi Biotec, Clone: REA897; Model: 130-114-861) was used as the antibody targeting the CD90 antigen, the APC anti-human CD105 antibody (Miltenyi Biotec, Clone: REA794; Model: 130-112-166) was used as the antibody targeting the CD105 antigen, the APC anti-human CD166 antibody (Miltenyi Biotec, Clone: REA442; Model: 130-106-576) was used as the antibody targeting the CD166 antigen, the APC anti-human CD45 antibody (Miltenyi Biotec, Clone: REA747; Model: 130-110-633) was used as the antibody targeting the CD45 antigen, and the APC anti-human CD326 antibody (Miltenyi Biotec, Clone: REA764; Model: 130-111-000) was used as the antibody targeting the CD326 antigen. .. Surface antigen analysis was performed using Guava easyCyte (Merck) by subjecting 30,000 cells to analysis and designating the flow rate at 35.4 μl/min.



    Similar Products

    96
    Miltenyi Biotec cd45 apc antibody
    Cd45 Apc Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/CD45+Antibody%2C+anti-human%2C+REAfinity/pmc13371841-54-17-19
    Average 96 stars, based on 1 article reviews
    cd45 apc antibody - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd45 apc
    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of <t>CD45</t> + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.
    Cd45 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/CD45+Antibody%2C+anti-human%2C+REAfinity/pmc13375545-449-38-40
    Average 96 stars, based on 1 article reviews
    cd45 apc - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec apc cd45
    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of <t>CD45</t> + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.
    Apc Cd45, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/CD11b+Antibody%2C+anti-human%2Fmouse/pm42217185-282-10-11
    Average 95 stars, based on 1 article reviews
    apc cd45 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec anti human cd45 apc
    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of <t>CD45</t> + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.
    Anti Human Cd45 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/CD45+Antibody%2C+anti-human/pmc13053254-44-12-15
    Average 96 stars, based on 1 article reviews
    anti human cd45 apc - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    94
    Cytek Biosciences cd45 hi30
    Characterization of the representative human HPCs (A) Flow cytometry on HPC markers, CD34, CD41, CD253a, <t>CD45,</t> and CD43. Cellular events were subjected to debris removal (top-left), doublet removal (top-middle), and stained with DAPI (top-right) to gate for the analysis of viable cells. A combination of surface markers was used to evaluate the HPC identity (bottom panel) with expression of 92.1% CD34+/CD43+/CD253a+/CD41+/CD45-cells. (B) Representative images of HPC differentiation from Day 7 (D7) HPC, Day 14 (D14), Day 19 (D19) microglia to Day 38 (D38) mature microglia. Scale bar: 100 μm.
    Cd45 Hi30, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/APC-Cyanine7+Anti-Human+CD45/pmc12856185-108-0-4
    Average 94 stars, based on 1 article reviews
    cd45 hi30 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec apc anti human cd45 antibody
    Characterization of the representative human HPCs (A) Flow cytometry on HPC markers, CD34, CD41, CD253a, <t>CD45,</t> and CD43. Cellular events were subjected to debris removal (top-left), doublet removal (top-middle), and stained with DAPI (top-right) to gate for the analysis of viable cells. A combination of surface markers was used to evaluate the HPC identity (bottom panel) with expression of 92.1% CD34+/CD43+/CD253a+/CD41+/CD45-cells. (B) Representative images of HPC differentiation from Day 7 (D7) HPC, Day 14 (D14), Day 19 (D19) microglia to Day 38 (D38) mature microglia. Scale bar: 100 μm.
    Apc Anti Human Cd45 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/CD45+Antibody%2C+anti-human%2C+REAfinity/us12564607-324-122-126
    Average 96 stars, based on 1 article reviews
    apc anti human cd45 antibody - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology anti cd45 apc
    Characterization of the representative human HPCs (A) Flow cytometry on HPC markers, CD34, CD41, CD253a, <t>CD45,</t> and CD43. Cellular events were subjected to debris removal (top-left), doublet removal (top-middle), and stained with DAPI (top-right) to gate for the analysis of viable cells. A combination of surface markers was used to evaluate the HPC identity (bottom panel) with expression of 92.1% CD34+/CD43+/CD253a+/CD41+/CD45-cells. (B) Representative images of HPC differentiation from Day 7 (D7) HPC, Day 14 (D14), Day 19 (D19) microglia to Day 38 (D38) mature microglia. Scale bar: 100 μm.
    Anti Cd45 Apc, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/APC+Anti-Human+CD45+Antibody/pmc12659052-36-12-13
    Average 93 stars, based on 1 article reviews
    anti cd45 apc - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    Cytek Biosciences human cd45 tonbo biosciences
    Characterization of the representative human HPCs (A) Flow cytometry on HPC markers, CD34, CD41, CD253a, <t>CD45,</t> and CD43. Cellular events were subjected to debris removal (top-left), doublet removal (top-middle), and stained with DAPI (top-right) to gate for the analysis of viable cells. A combination of surface markers was used to evaluate the HPC identity (bottom panel) with expression of 92.1% CD34+/CD43+/CD253a+/CD41+/CD45-cells. (B) Representative images of HPC differentiation from Day 7 (D7) HPC, Day 14 (D14), Day 19 (D19) microglia to Day 38 (D38) mature microglia. Scale bar: 100 μm.
    Human Cd45 Tonbo Biosciences, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/APC-Cyanine7+Anti-Human+CD45/pm41166305-276-123-125
    Average 94 stars, based on 1 article reviews
    human cd45 tonbo biosciences - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec human cd45
    Characterization of the representative human HPCs (A) Flow cytometry on HPC markers, CD34, CD41, CD253a, <t>CD45,</t> and CD43. Cellular events were subjected to debris removal (top-left), doublet removal (top-middle), and stained with DAPI (top-right) to gate for the analysis of viable cells. A combination of surface markers was used to evaluate the HPC identity (bottom panel) with expression of 92.1% CD34+/CD43+/CD253a+/CD41+/CD45-cells. (B) Representative images of HPC differentiation from Day 7 (D7) HPC, Day 14 (D14), Day 19 (D19) microglia to Day 38 (D38) mature microglia. Scale bar: 100 μm.
    Human Cd45, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/apc+anti+human+cd45+antibody/CD45+Antibody%2C+anti-human%2C+APC-Vio+770/pm41015034-408-27-31
    Average 96 stars, based on 1 article reviews
    human cd45 - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    Image Search Results


    Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.

    Journal: Nature Medicine

    Article Title: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

    doi: 10.1038/s41591-026-04449-9

    Figure Lengend Snippet: Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.

    Article Snippet: Antibodies for the TCR/DC panel included TCRγδ Vio Blue (Miltenyi Biotec, cat. no.1 30-119-619), TCRαβ FITC (Miltenyi Biotec, cat. no. 130-113-538), CD83 PE (Miltenyi Biotec, cat. no. 130-110-503), CD3 Per CP Vio-770 (Miltenyi Biotec, cat. no. 130-113-141) and CD45 APC (Miltenyi Biotec, cat. no. 130-110-633).

    Techniques: Enzyme-linked Immunospot, Whisker Assay

    Characterization of the representative human HPCs (A) Flow cytometry on HPC markers, CD34, CD41, CD253a, CD45, and CD43. Cellular events were subjected to debris removal (top-left), doublet removal (top-middle), and stained with DAPI (top-right) to gate for the analysis of viable cells. A combination of surface markers was used to evaluate the HPC identity (bottom panel) with expression of 92.1% CD34+/CD43+/CD253a+/CD41+/CD45-cells. (B) Representative images of HPC differentiation from Day 7 (D7) HPC, Day 14 (D14), Day 19 (D19) microglia to Day 38 (D38) mature microglia. Scale bar: 100 μm.

    Journal: STAR Protocols

    Article Title: Protocol for morphogen-guided differentiation of brain cell types using human induced pluripotent stem cells

    doi: 10.1016/j.xpro.2025.104339

    Figure Lengend Snippet: Characterization of the representative human HPCs (A) Flow cytometry on HPC markers, CD34, CD41, CD253a, CD45, and CD43. Cellular events were subjected to debris removal (top-left), doublet removal (top-middle), and stained with DAPI (top-right) to gate for the analysis of viable cells. A combination of surface markers was used to evaluate the HPC identity (bottom panel) with expression of 92.1% CD34+/CD43+/CD253a+/CD41+/CD45-cells. (B) Representative images of HPC differentiation from Day 7 (D7) HPC, Day 14 (D14), Day 19 (D19) microglia to Day 38 (D38) mature microglia. Scale bar: 100 μm.

    Article Snippet: CD45 (HI30) (1:50) , Tonbo Bioscience , Cat# 25-0459, RRID: AB_2621631.

    Techniques: Flow Cytometry, Staining, Expressing